| Public | TASE:APOS |
| Website | aposense.com |
| Category | BioTech |
| Phone | 972-3-924-72-11 |
| info@aposense.com | |
| Employees | |
| Description | Targeting New Healthcare Horizons |
| TOTAL | $10.3M |
| FUNDING TOTAL | $10.3M |
| Venture Round, 8/08 Zeigler Meditech Equity Partners Pontifax Docor International Management Federman Holdings Technorov Bargal R&D Investment Phoenix Insurance Polar Investments Clal Biotechnology | $7.3M |
| Venture Round, 5/10 Ziegler Meditech Equity Partners Pontifax | $3M |
Aposense® (formerly NST) is a clinical stage molecular imaging and drug development company, with a pipeline of products based on its patented platform technology for targeting apoptosis (programmed cell death) in vivo. Aposense® is translating the science of Apoptosis (programmed cell death) into personalized patient care in multiple disease categories, including oncology, cardiology and neurology. Targeting of this important biological process in-vivo opens opportunities for real-time clinical imaging of disease activity and targeted therapy.
